Different measurements, different failure modes
Protein aggregation can involve soluble oligomers, insoluble particles or concentration-dependent self-association. Conformational unfolding, interfaces, pH, ionic strength, temperature and handling can contribute. No single early assay fully characterizes those risks. For antibody candidates, combine a molecular-size readout with an appropriate physical-stability readout, then add orthogonal measurements when a result is ambiguous or consequential.
| Method | Useful readout | Important limitation |
|---|---|---|
| SEC / SEC-HPLC | Soluble monomer, higher-/lower-molecular-weight species and chromatographic behavior | Column interactions or dilution may alter apparent aggregation; insoluble particles may not enter the column |
| DLS | Hydrodynamic size distribution and larger-species sensitivity in solution | Intensity-weighted signals can be dominated by a small number of large particles; not a specific identity assay |
| nanoDSF | Intrinsic fluorescence change upon heating; an apparent thermal transition and possibly aggregation onset | Heating-ramp conditions do not equate to real-time shelf life; curves may be complex or non-interpretable |
| Visual / turbidity review | Visible change, precipitation or gross sample loss | Insensitive to many soluble species; not a substitute for quantitative analysis |
What does a clean SEC trace actually mean?
A high monomer percentage at a single time point and low concentration is useful, but it does not prove chemical or physical stability under handling or storage. Report the chromatographic method, sample concentration, total recovery, integration settings and relevant blanks. Peak tailing can reflect interactions with the stationary phase rather than a simple monomer/aggregate distinction.
Compare candidate samples under harmonized conditions. Follow-up work might include repeat SEC after a defined stress, a different stationary phase, or an orthogonal particle-sensitive method when the interpretation matters.
Design a small, decision-relevant stress screen
- Baseline: collect the initial assay results as close as possible to purification under a documented handling history.
- Stress selection: choose a limited temperature, agitation, freeze-thaw or hold-time challenge relevant to the next research step, not an arbitrary stress battery.
- Matched comparison: use the same container, fill volume, concentration and analysis interval where possible.
- Functional link: reassess binding or bioactivity for shortlisted samples when physical changes could affect interpretation.
- Interpretation: distinguish reversible association, loss to surfaces, fragmentation and aggregation where the data allow.
Accelerated stress is a risk-screening tool; it is not a validated prediction of clinical shelf life or a replacement for later formulation stability programs.
Red flags and evidence quality
Decision-relevant findings can include low recovery after handling, growing high-molecular-weight peaks, poorly reproducible thermal traces or divergent assay responses that warrant troubleshooting. Set criteria relative to the research use, target and format. A universally applicable Tm or SEC cut-off is rarely defensible at a discovery stage.
Request raw chromatograms, fluorescence curves, acquisition parameters, replicates or technical repeats, clear controls and a concise list of alternative explanations. For an AI-generated candidate, uncertainty in the binding claim and in the physical-stability claim should be reported separately.
Scientific context
- Structure, heterogeneity and developability assessment of therapeutic antibodies (2019)
- Blueprint for antibody biologics developability (2023)
Background reading; links do not imply endorsement or a service partnership.